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Abstract
Background: Prognostic abilities of medical parameters, which are scoring systems, measurements and biomarkers,
are important for stratifying critically ill patients. Indocyanine green plasma disappearance (ICG-PDR) is an
established clinical tool for the assessment of liver perfusion and function. Copeptin, MR-proANP and pro-ADM are
biomarkers whose prognostic value is still unclear. The goal of this prospective study was to evaluate ICG-PDR,
copeptin, MR-proANP and pro-ADM to predict prolonged length of stay (pLOS) in the ICU.
Methods: This study was conducted as a prospective single center study including 110 consecutively admitted ICU
patients. Primary endpoint was prolonged length of stay (pLOS) in the ICU, defined as more than three days of stay
there.
Results: ROC analysis showed an AUC of 0.73 for ICG-PDR, 0.70 for SAPS II, 0.65 for MR-proANP, 0.64 for pro-ADM
and 0.54 for copeptin for pLOS in the ICU.
Conclusions: The prediction of pLOS in the ICU might be better by means of ICG-PDR than with the new
biomarkers copeptin, MR-proANP or pro-ADM. Nevertheless, there is more need for research to evaluate whether
ICG-PDR is an overall prognostic marker for pLOS.
Trial registration: (ClinicalTrials.gov number, NCT01126554).
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Background
The prognostic abilities of medical parameters, which
are scoring systems, measurements and biomarkers, are
important for stratifying critically ill patients [1] to
optimize resources and further investigation in this area
is warranted.
The Simplified Acute Physiology Score (SAPS II) is a
validated scoring system to predict mortality in critically
ill patients [2]. Regardless of the underlying diagnosis,
the combination of 17 variables allows reliable outcome
prediction. SAPS II models have proved to be competitive
to the SOFA (Sequential Organ Failure Assessment) based
score models [3]. However, SAPS II scoring is less reliable
for prediction of length of stay (LOS) in the ICU [4,5].
Indocyanine green plasma disappearance rate (ICG-
PDR) is closely correlated to hepatic function due to its
hepatic metabolization. The non-invasive ICG measure-
ment, based on pulse dye measurement using a finger-
clip, has been shown to correlate well with the classical
measurements [6] and is non-invasive and easy to use.
ICG-PDR has proven to predict mortality in critically ill
patients comparable to the SAPS II score [7], as well as
to predict complications in liver cirrhosis patients [8] and
posthepatectomy liver failure [9]. The capability of ICG-
PDR to predict LOS in the ICU remains elusive.
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Several new biomarkers are under investigation in the
ICU for critically ill patients.
Copeptin, a peptide of 39 amino acids, is the C-terminal
part of pro-arginine vasopressin also called C-terminal-
pro-arginine vasopressin (CT-proAVP). It reveals several
physiologic actions: arteriolar vasoconstriction (V1-recep-
tor mediated), an anti-diuretic effect in the kidneys (V2-
receptor mediated) [10] and is probably involved in the
secretion of ACTH (V3-receptor mediated) [11]. It has
been proven to predict mortality in patients with commu-
nity acquired pneumonia [12], stroke [13], and traumatic
brain injury [14].
Atrial natriuretic peptide (ANP) is a counter-regulatory
hormone synthesized in the heart, being cleaved and re-
leased during hemodynamic stress or myocardial injury.
High mid-region proANP levels (MR-proANP) are associ-
ated with high mortality in patients with acute myocardial
infarction [15] and chronic obstructive pulmonary disease
(COPD) exacerbation [16].
Proadrenomedullin (pro-ADM) is a 185 amino acid-long
precursor of the vasodilator adrenomedullin (52 amino
acids). It is released during severe infection, especially sep-
tic shock and is influenced by age, body mass index and
glomerular filtration rate in healthy volunteers [17]. Like
MR-proANP, it has been proven to predict mortality in pa-
tients with COPD exacerbation [18] and acute myocardial
infarction [19,20].
While these biomarkers have proven useful to predict
mortality in different settings, to our knowledge no data
are available concerning their predictive value of ICU
pLOS. The goal of this study was to investigate the accur-
acy of ICG-PDR, SAPS II, copeptin, MR-proANP, pro-
ADM and other established biomarkers for prediction of
pLOS in the ICU.
Methods
Study design
This prospective single center study was conducted at
the surgical ICU (10 beds, 920 patients in the year 2010)
at the University Hospital of Zurich from 1 August 2010
to 31 October 2010. During this period, all patients ad-
mitted to our ICU were eligible for inclusion regardless
of underlying disease or reason for admission. Exclusion
criteria were: age below 18 years, pregnancy, inclusion in
another study, patients or relatives not able to understand
the German language or known iodine allergy (a compo-
nent of ICG). The aim was the comparison of the prog-
nostic value of the ICG-liver test and SAPS II score on the
one hand with new biomarkers (copeptin, pro-ADM and
MR-proANP), and on the other hand to established bio-
markers (bilirubin, aspartate aminotransferase (AST), ala-
nine aminotransferase (ALT), alkaline phosphatase (AP),
International Normalized Ratio (INR), hemoglobin, white
blood cell (WBC) count, activated partial thromboplastin
time (aPTT), dDimer, cystatin C, C-reactive protein
(CRP), procalcitonin (PCT), IL-6, the B-type natriuretic
peptide (NT-proBNP) Primary endpoint was prolonged
length of stay (pLOS) in the ICU, represented by more
than three days. A power calculation was performed with
the assumption of 5% mortality and 30% of pLOS in the
patient population; therefore 110 patients with an esti-
mated drop-out of 10% were prospectively included. Ini-
tially, mortality was considered as primary endpoint but
the financial burden of such a large sample size (hundreds
of patients) was unaffordable. Therefore, the study was
performed with the endpoint pLOS.
The study was approved by the local ethical committee
and informed consent was achieved by all patients or
next of kin. The trial was registered as ClinicalTrials.gov
number, NCT 01126554.
Study protocol
After achievement of informed consent, patients were in-
cluded into the study. Baseline characteristics were col-
lected. Reason for ICU admission was classified as visceral
surgery, thoracic surgery, medical disease and others.
Blood samples used for the analysis were drawn within
two hours after admission. The ICG-liver testing was
performed non-invasively within 60 minutes after ICU ad-
mission by pulse spectrophotometry (LiMON®, Pulsion
Medical Systems AG, Munich, Germany). Following an
intravenous bolus injection of ICG (0.25 mg/kg; ICG
Pulsion Medical Systems AG, Munich, Germany), plasma
ICG concentrations were determined by pulse spectro-
photometry with a finger-clip sensor. Using two near-
infrared wavelengths, the plasma disappearance rate of
ICG (ICG-PDR) was calculated automatically by the
time course of the blood ICG concentration. Normal
values are defined as ICG-PDR ≥ 16%/minute. SAPS II
score was calculated after 24 hours.
Laboratory analysis
Venous whole blood samples were collected in tubes con-
taining either ethylenediaminetetraacetic acid (EDTA) or
lithium heparin. Copeptin, MR-proANP and pro-ADM
were determined in EDTA plasma by Time-Resolved Amp-
lified Cryptate Emission (TRACE) technology on the
KRYPTOR analyzer (BRAHMS, Henningsdorf, Germany).
Plasma levels of PCT and NT-proBNP were measured
by electrochemiluminescence immunoassays on a COBAS
8000 modular analyzer (Roche Diagnostics, Rotkreuz,
Switzerland). IL-6 levels were analyzed using a chemi-
luminescence enzyme immunoassay on an Immulite
2500 analyzer (Siemens Healthcare Diagnostics, Zurich,
Switzerland) and cystatin C was measured by immuno-
nephelometry on a Behring nephelometer system (Dade
Behring, Dudingen, Switzerland).
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Plasma concentrations of AST, ALT, AP, bilirubin and
CRP, were measured on a COBAS 8000 modular analyzer
(Roche Diagnostics, Rotkreuz, Switzerland).
Statistical analysis
All subjects were grouped into the two clusters: ICU
stay ≤ three days and prolonged ICU stay (>three days).
Univariate statistics of the biomarkers and tests applied
in this study were done by Mann-Whitney U-test or
Fishers exact test as appropriate. All P-values were
considered two-sided and statistical significance was
considered as P < 0.05. Biomarkers and tests showing
statistical significance were further examined by receiver
operating characteristics (ROC) analysis. Comparison of
ROC analysis was done by comparison of area under the
curve (AUC).
Accuracy of ICG, SAPS II, IL-6, dDimer, NT-proBNP,
MR-proANP and pro-ADM were tested and the cut offs
defined (significance and specificity based) by ROC ana-
lysis. Statistics were done with SPSS for Windows ver-
sion 18.0 (SPSS, Chicago, IL, USA).
Results
Baseline characteristics
We screened 117 patients admitted to the ICU during the
study period. Seven patients were not enrolled due to ex-
clusion criteria. After a drop-out of four patients, because
of two lost blood sample sets and two withdrawals of con-
sent, the data of 106 patients were analyzed.
Forty-one of the patients were female (38.7%) and 65
male (61.3%). ICU mortality was 2.8% (n = 3), whereas
hospital mortality was 6.6% (n = 7). The four diagnostic
groups were: visceral surgery 53 patients (50.0%), thoracic
surgery 27 patients (25.5%), medical group 7 patients
(6.6%) and others 19 patients (17.9%). Thirty-eight pa-
tients were ventilated on admission to the ICU, whereas
28 could be extubated within the first 12 hours after ad-
mission. In the visceral surgery group, 20 underwent liver
surgery (wedge resection, left or right hemihepatectomy).
Eight patients had preexisting liver dysfunction (2 Child C
and 6 Child B cirrhosis).
Overall, 25 (23.6%) patients had a prolonged length of
stay in the ICU. There was no statistical significant
difference between the diagnostic groups in respect to
pLOS or normal LOS. The median of LOS was 4.2 days
in all patients.
Univariate data
The univariate analysis of laboratory values between the
short stay and prolonged stay groups in the ICU and
baseline criteria are shown in Table 1. There was no
statistical difference in baseline criteria between the
diagnostic groups. There was a statistical significance
between the two groups concerning ICG-PDR (P =
0.03), bilirubin (P = 0.003), AST (P = 0.02), ALT (P =
0.05), SAPS II (P = 0.01), IL-6 (P = 0.005), Ddimer (P =
0.02), aPTT (0.05), MR-proANP (P = 0.03) and pro-
ADM (P = 0.03) while copeptin did not show a statistical
significant difference (P = 0.67).
ROC analysis
The ROC analysis is shown in Table 2. ICG-PDR (AUC
0.73) and SAPS II (AUC 0.7) did perform better for pre-
diction for prolonged length of stay in the ICU than the
new biomarkers MR-proANP (AUC 0.65), pro-ADM
(AUC 0.64) and copeptin (AUC 0.54). There was no statis-
tical difference between ICG-PDR and SAPS II (P = 0.78).
Discussion
The main finding of this study is the value of ICG-PDR
in prediction of pLOS in the ICU. The measurement is
easy to perform and, in contrast to the SAPS II score,
consists of only one value and not of seventeen values,
Table 1 Baseline, clinical and laboratory parameters
Parameter ICU stay > 3 days ICU stay ≤ 3 days P
(n = 25) (n = 81)
Age (years) 64 (61 to 70) 65 (48 to 73) 0.89
ICG-PDR (%/minute) 17 (12 to 24) 22.5 (17 to 29) 0.03
Bilirubin (μmol/l) 15 (9 to 31) 9 (6 to 15) 0.003
AST (U/l) 84 (35 to 439) 36 (23 to 90) 0.02
ALT(U/l) 57 (23 to 403) 29 (16 to 70) 0.05
AP (U/l) 63 (46 to 132) 52 (41 to 75) 0.26
Quick (%) 86 (46 to 106) 89 (63 to 105) 0.50
Hemoglobin (g/dl) 9 (8 to 13) 10 (9 to 12) 0.79
WBC (g/l) 10 (9 to 12) 10 (7 to 14) 0.82
aPTT (seconds) 33 (29 to 40) 29 (25 to 33) 0.05
dDimer (mg/l) 3 (2 to 5) 2 (1 to 3) 0.02
Cystatin C (mg/l) 1 (1 to 1) 1 (1 to 1) 0.72
CRP (mg/l) 31 (5 to 81) 15 (5 to 70) 0.87
PCT (μg/l) 1 (1 to 2) 2 (1 to 4) 0.41
IL-6 (ng/l) 403 (190 to 853) 177 (55 to 314) 0.005
NT-proBNP (ng/l) 745 (111 to 1875) 245 (68 to 957) 0.09
MR-proANP (pmol/l) 268 (119 to 342) 140 (94 to 214) 0.03
Pro-ADM (nmol/l) 2 (1 to 3) 1 (1 to 2) 0.03
Copeptin (pmol/l) 96 (20 to 171) 94 (28 to 230) 0.67
SAPS II (points) 31 (26 to 43) 24 (18 to 30) 0.01
Data presented as median (IQR). AP, alkaline phosphatase; aPTT, activated
partial thromboplastin time; ALT, alanine aminotransferase; AST, aspartate
aminotransferase; CRP, C-reactive protein; ICG-PDR, indocyanine green plasma
disappearance rate; IL, interleukin; MR-proANP, pro-atrial natriuretic peptide;
NT-proBNP, B-type natriuretic peptide; PCT, procalcitonin; Pro-ADM,
proadrenomedullin; SAPS II, Simplified Acute Physiology Score; WBC, white
blood cells. Quick, prothrombin time.
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which made its application time-saving and quick. As
ICG-PDR reflects liver function, this finding confirms
that impaired liver function is of crucial importance in
the assessment and prognosis of critical care patients.
Impaired liver function shows a wide spectrum of
immunosuppressant effects, metabolic and pharmaco-
logical disturbances and coagulation disorders. Thus,
ICG-PDR might be a representative surrogate for a
summation of these effects with negative influence for
intensive care patients. This suggestion is supported by
the fact that in our study the patients with pLOS also
had higher serum bilirubin, AST and ALT levels as well
as a prolonged aPTT. There was no better discrimin-
ation of MR-proANP and pro-ADM between long- and
short-term LOS in the ICU than ICG-PDR. A potential
explanation might be that the heterogeneous population
presented with impaired liver function at a grade of se-
verity, but the MR-proANP and pro-ADM pathways
were activated by different underlying pathologies and
probably do not reflect the severity of disease. Never-
theless, there are patient populations in which those
markers showed a good predictive accuracy in predic-
tion of outcome [18,21,22], but still we lack data about
ICU patients. A recent study by Guignant et al. reported
an association between elevated pro-ADM levels and
nosocomial infection in patients after septic shock,
whereas copeptin and MR-proANP showed no correl-
ation in this population [23].
Copeptin failed to discriminate LOS between long-
term and short-term patients; therefore, its prognostic
value seems to be weak in this area. One reason might
be that the main trigger for copeptin release - as a part
of the vasopressin pathway - is hypovolemia, which, in
our study population of postsurgical and resuscitated
medical ICU patients, was definitely not the case. In our
institution, most of the unstable patients are monitored
by the PiCCO-system (Pulsion, Munich, Germany),
Swan-Ganz catheter or by means of echocardiography,
which might have led to an adequate volemia at the
point of admission.
One important study limitation is the heterogeneous
and small patient population, which might explain some
of the results. Nevertheless, our cohort was a representa-
tive ICU population of a university hospital center with
patients of considerable pathological complexity and se-
verity. Furthermore, we assessed only one data point of
every marker per patient on admission. Whether a re-
petitive regimen of measurement at, for instance, day 3
or 5, would have shown different results, remains un-
clear. These findings might help - but only in combin-
ation with clinical signs and the experience of the ICU
staff - to utilize and optimize the scarce ICU resources
by early stratification, which might lead to earlier but
safe discharge to intermediate care units.
Conclusion
The prediction of pLOS in the ICU might be better by
means of ICG-PDR than with the new biomarkers copep-
tin, MR-proANP or pro-ADM. Nevertheless, there is a
need for further research to evaluate whether ICG-PDR is
an overall prognostic marker for pLOS.
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Table 2 Receiver operating characteristics (ROC) statistics
Parameter AUC (95% CI) Cut-off Sensitivity
(%)
Specificity
(%)
ICG (%) 0.73 (0.56 to 0.88) 11.5 71 71
SAPS II (points) 0.70 (0.54 to 0.84) 25.5 76 64
IL-6 (ng/l) 0.68 (0.52 to 0.84) 289 59 74
dDimer (mg/l) 0.67 (0.49 to 0.85) 2.5 59 72
NT-proBNP (ng/l) 0.67 (0.51 to 0.84) 947 53 82
MR-proANP
(pmol/l)
0.65 (0.49 to 0.81) 209 59 74
Pro-ADM (nmol/l) 0.64 (0.48 to 0.81) 2.5 41 89
ICG, indocyanine green; IL, interleukin; MR-proANP, pro-atrial natriuretic
peptide; NT-proBNP, B-type natriuretic peptide; Pro-ADM, proadrenomedullin;
SAPS II, Simplified Acute Physiology Score.
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